Disease management in a patient diagnosed with COVID-19 disease during induction intravesical BCG therapy: A case report and review of the literature

Ok, Fesih; Durmuş, Emrullah

doi:10.1177/03915603211001670

Cited by 3 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, maintenance medication may be discontinued after three months if the risk of COVID-19 infection has decreased [ 28 , 29 ]. If patients who undergo intravesical BCG therapy are discovered to be infected with SARS-CoV-2, there is data promoting the interruption of instillations for three weeks to allow for full recovery, followed by treatment completion for six weeks, with a total duration of therapy not to exceed one year [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

A Retrospective Analysis of the Challenges of Urothelial Cancer Management during the COVID-19 Pandemic at a Single Academic Center in Romania

Barbos

Feciche²,

Bratosin

et al. 2023

Healthcare

View full text Add to dashboard Cite

The COVID-19 pandemic caused major changes in the healthcare sector due to adaptations required to hospitalize and treat an impressive number of patients. This retrospective study intended to collect reliable information on urothelial cancer patients in Romania. The primary objective was to compare the pre-pandemic and pandemic periods to observe the differences that occurred in the management of patients with urothelial carcinoma. The secondary objective was to determine the risk factors for urothelial cancer progression in the study cohort correlated with the COVID-19 pandemic. All patients that were diagnosed and treated at our clinic with a diagnosis of urothelial carcinoma (transitional cell carcinoma) during 2019–2021 were included in the current study. A total of 1122 eligible unique cases were identified during the study period. The number of patients who underwent intervention in the pre-pandemic year was 421, followed by a 22.6% decrease in 2020 to 326 cases and a 13.1% increase in 2021 to 375 cases. The proportion of muscle-invasive bladder cancer (MIBC) cases was significantly higher during the pandemic years, from 30.5% MIBC cases in 2019 to 37.4% in 2020 and 39.4% in 2021, suggesting a delay in presentations during the pandemic. Stage III and IV (TNM) cases were significantly more frequent, even though approximately 40% of all patients were operated on in stage I. The number of cystectomies increased significantly, from 5.2% in 2019 and 4.3% in 2020 to 10.1% in 2021, while the number of elective surgeries decreased, although no significant difference was observed regarding the in-hospital mortality and disease progression at six months. Patients with stage III and IV at presentation had the highest likelihood of disease progression at six months (HR = 5.61). Distant invasion was the second highest risk factor (HR = 5.13), followed by MIBC type (HR = 2.49). Nevertheless, the duration of hospitalization and year of diagnosis during the COVID-19 pandemic were not significant risk factors for cancer progression at six months. It can be concluded that there was a significant delay in patient presentations in 2020, and we advocate for increased public health awareness for urothelial cancer and increased attention toward the screening and management of these patients in the following years.

show abstract

Section: Discussionmentioning

confidence: 99%

A Retrospective Analysis of the Challenges of Urothelial Cancer Management during the COVID-19 Pandemic at a Single Academic Center in Romania

Barbos

Feciche²,

Bratosin

et al. 2023

Healthcare

View full text Add to dashboard Cite

show abstract

“…Similarly, in their respective studies, Ficarra et al and Stensland et al categorized urological cancer cases and set a priority order [16,17]. Many different clinics have managed patients in line with these categories and provided similar recommendations [18,19]. We also postponed elective operations and hospitalizations in our clinic by accepting only surgical patients in the high priority group.…”

mentioning

confidence: 93%

The impact of the COVID-19 pandemic on the urology practice in a large tertiary hospital

DÜNDAR

Erkan

2022

The European Research Journal

View full text Add to dashboard Cite

Objectives: We aimed to reveal how four different areas that are important in the functioning of the urology clinic (outpatient clinic, inpatient clinic, operating room, and consultations) were affected during the COVID-19 pandemic. Methods: Patients admitted to the surgical branches between March 11, 2018 and March 10, 2021 were retrospectively evaluated in terms of their demographic data. The data between these dates were analyzed by dividing the patients into three groups as Groups A, B, and C for the pandemic period, the year before the pandemic, and two years before the pandemic, respectively. Results: A total of 1,222,967 patients were included in the study. During the pandemic period, the number of urology outpatient clinic admissions decreased by more than half compared to the previous years (37,471, 93,582, and 89,031 for Groups A, B, and C, respectively). Admissions to the urology inpatient clinic decreased both numerically and proportionally when compared to the other surgical branches (1,301 [5.1%] for Group A, 3,884 [7.7%] for Group B, and 3,761 [7.7%] for Group C]). While the mortality rate did not change proportionally in the urology clinic in all groups (0.3%), it increased both numerically and proportionally in all surgical branches (339 [1.3%], 304 [0.6%], and 256 [0.5%]). Conclusions: Admissions to the urology clinic were determined to have decreased during the pandemic compared to the pre-pandemic period, especially due to restriction measures taken by countries and concerns about the unknowns of the disease. As a result of this decrease, the number of operations and the number of hospitalized patients were also reduced. Although the mortality rate was not affected in the short-term follow-up of patients, long-term outcomes remain uncertain.

show abstract

“…However, maintenance therapy beyond three months may be omitted until the risk of COVID-19 infection is diminished [ 15 , 16 ]. If patients undergoing intravesical BCG therapy are found to be infected by COVID-19, there is evidence supporting interruption of instillations for three weeks, allowing for a full recovery, followed by treatment completion for six weeks, with a total duration of therapy not exceeding one year [ 17 ].…”

mentioning

confidence: 99%

Urothelial Carcinoma in COVID-19: Lessons From a Pandemic and Their Impact on Clinical Practice

et al. 2021

View full text Add to dashboard Cite

The COVID-19 pandemic has modified the management of urothelial carcinoma (UC). Eighteen months after the onset of the pandemic, a scoping narrative review was able to state that radical cystectomy for UC should not be delayed beyond 10 weeks when neoadjuvant chemotherapy (NAC) was administered and 12 weeks when it was not. NAC should be considered when imminent chemotherapy cannot be performed. Early cystectomy should not be delayed when indicated for patients with high-risk non-MIBC. Patients with non-MIBC should still receive their induction doses of intravesical instillations. Diagnostic cystoscopy should not be deferred in symptomatic patients. Surgical management of upper tract urothelial carcinoma (UTUC) allows for a wider deferral interval.

show abstract

Disease management in a patient diagnosed with COVID-19 disease during induction intravesical BCG therapy: A case report and review of the literature

Cited by 3 publications

References 4 publications

A Retrospective Analysis of the Challenges of Urothelial Cancer Management during the COVID-19 Pandemic at a Single Academic Center in Romania

A Retrospective Analysis of the Challenges of Urothelial Cancer Management during the COVID-19 Pandemic at a Single Academic Center in Romania

The impact of the COVID-19 pandemic on the urology practice in a large tertiary hospital

Urothelial Carcinoma in COVID-19: Lessons From a Pandemic and Their Impact on Clinical Practice

Contact Info

Product

Resources

About